Mariana P. Socal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mariana P. Socal has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Gerard F. Anderson
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
10 shared publicationsGe Bai
Johns Hopkins Carey Business School, Washington, DC
8 shared publications- Jeromie Ballreich
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205
7 shared publications - Gerard Anderson
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205
5 shared publications - Yunxiang Sun
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205
5 shared publications - Gerard F. Anderson
Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
4 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (9)
FDA drug quality assurance inspections: frequency, outcomes, and time to reinspection, 2008-2025
Background: The U.S. Food and Drug Administration (FDA) inspections are central to oversight of the pharmaceutical manufacturing base, but long-term inspection and reinspection patterns remain incompletely characterized. Methods: We analyzed 25 629 FDA Drug Quality Assurance inspections conducted from October 2008 through December 2025. We described annual, regional, and outcome patterns. Linking inspections to facilities, we examined time to reinspection according to the outcome of preceding inspections. Results: Annual Drug Quality Assurance inspections declined from 1594 in 2019 to 461 in 2020 and increased to 1218 in 2025. The United States remained the largest single region of inspection activity, but its contribution declined over time. The proportion of favorable inspection outcomes (no action indicated—NAI) decreased from 40.0% before the pandemic to 19.3% during and 23.7% after. Unfavorable outcomes (voluntary action indicated—VAI—and official action indicated—OAI) increased accordingly. The mean reinspection interval was 3.18 years after NAI, 2.96 after VAI, and 2.12 after OAI (P < .001). Median times were 4.08, 3.51, and 3.02 years, respectively. Conclusion: FDA inspection activity had not returned to prepandemic levels by 2025. Unfavorable inspection outcomes were associated with earlier reinspection, consistent with risk-responsive oversight. However, the available data cannot establish whether follow-up was timely or adequate.
- 27 August 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (9)
Open AccessFDA drug quality assurance inspections: frequency, outcomes, and time to reinspection, 2008-2025
Background: The U.S. Food and Drug Administration (FDA) inspections are central to oversight of the pharmaceutical manufacturing base, but long-term inspection and reinspection patterns remain incompletely characterized. Methods: We analyzed 25 629 FDA Drug Quality Assurance inspections conducted from October 2008 through December 2025. We described annual, regional, and outcome patterns. Linking inspections to facilities, we examined time to reinspection according to the outcome of preceding inspections. Results: Annual Drug Quality Assurance inspections declined from 1594 in 2019 to 461 in 2020 and increased to 1218 in 2025. The United States remained the largest single region of inspection activity, but its contribution declined over time. The proportion of favorable inspection outcomes (no action indicated—NAI) decreased from 40.0% before the pandemic to 19.3% during and 23.7% after. Unfavorable outcomes (voluntary action indicated—VAI—and official action indicated—OAI) increased accordingly. The mean reinspection interval was 3.18 years after NAI, 2.96 after VAI, and 2.12 after OAI (P < .001). Median times were 4.08, 3.51, and 3.02 years, respectively. Conclusion: FDA inspection activity had not returned to prepandemic levels by 2025. Unfavorable inspection outcomes were associated with earlier reinspection, consistent with risk-responsive oversight. However, the available data cannot establish whether follow-up was timely or adequate.
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (3) , e200623
Bridging the Funding Gap in Drug Development for Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few effective treatments and high clinical trial failure rates. Since 1995, only 3 drugs riluzole, edaravone, and tofersen have gained approval from the Food and Drug Administration, all offering modest benefits. Challenges in ALS drug development include poor translational preclinical models, underpowered early-phase trials, and the high cost of late-stage development. Despite federal initiatives such as the Accelerating Access to Critical Therapies for ALS Act and the ALL ALS Consortium, critical gaps remain in funding large multisite trials and sustaining research networks. Accelerating progress requires strengthening national registries, expanding adaptive trial platforms, integrating existing networks, and adopting innovative funding models such as milestone-based public-private partnerships and reinvestment of licensing revenues. A coordinated, sustainable research and funding ecosystem could transform ALS therapy development and serve as a model for advancing treatments for other rare neurodegenerative and neurogenetic disorders.
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (3) , e200623
Bridging the Funding Gap in Drug Development for Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few effective treatments and high clinical trial failure rates. Since 1995, only 3 drugs riluzole, edaravone, and tofersen have gained approval from the Food and Drug Administration, all offering modest benefits. Challenges in ALS drug development include poor translational preclinical models, underpowered early-phase trials, and the high cost of late-stage development. Despite federal initiatives such as the Accelerating Access to Critical Therapies for ALS Act and the ALL ALS Consortium, critical gaps remain in funding large multisite trials and sustaining research networks. Accelerating progress requires strengthening national registries, expanding adaptive trial platforms, integrating existing networks, and adopting innovative funding models such as milestone-based public-private partnerships and reinvestment of licensing revenues. A coordinated, sustainable research and funding ecosystem could transform ALS therapy development and serve as a model for advancing treatments for other rare neurodegenerative and neurogenetic disorders.
- Open Access
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2611849
Insulin Patient Assistance Programs and Protected Heath Information
This cross-sectional study examines insulin patient assistant programs to assess what protected health information participants are required to provide and how it may be used or disclosed.
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2611849
Open AccessInsulin Patient Assistance Programs and Protected Heath Information
This cross-sectional study examines insulin patient assistant programs to assess what protected health information participants are required to provide and how it may be used or disclosed.
- 23 April 2026
- Published by Elsevier in The Journal of Pain
- Vol. 45, 106303
Understanding pain and pain management patterns in construction workers: A latent class analysis of cross-sectional survey data
- 23 April 2026
- Published by Elsevier in The Journal of Pain
- Vol. 45, 106303
Understanding pain and pain management patterns in construction workers: A latent class analysis of cross-sectional survey data
- Open Access
- 25 February 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e84968
Trends in Venture Capital Investment in AI-Driven Biopharmaceutical Startups
This study analyzes 2010-2024 venture capital trends in international artificial intelligence–driven biopharmaceutical startups, revealing rapid growth in discovery tool investments and concentrated US funding in California and Massachusetts.
- 25 February 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e84968
Open AccessTrends in Venture Capital Investment in AI-Driven Biopharmaceutical Startups
This study analyzes 2010-2024 venture capital trends in international artificial intelligence–driven biopharmaceutical startups, revealing rapid growth in discovery tool investments and concentrated US funding in California and Massachusetts.
- Open Access
- 23 December 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (2)
Potential impact of tariffs on active pharmaceutical ingredients on the price of US-made generic drugs
Introduction: The impact of tariffs on prescription drug prices has been poorly understood. Methods: Using US importation data 2019-2024, this study modeled the potential impact of tariffs on the prices of generic drugs manufactured in the United States with imported active pharmaceutical ingredients (APIs). Results: Under baseline assumptions a 100% worldwide tariff would result in average price increase of 30% (additional $21.15 per prescription) and a blended tariff based on rates proposed by the Federal Administration would result in an average price increase of 10% (additional $6.22 per prescription) for domestically produced generics using imported APIs. Estimates varied across drugs reflecting different API importation patterns. Assumptions on the tariff rate, the contribution of the API cost to the final drug price, and on the supply chain's ability to absorb the added tariff contributed markedly to determining the final price. The study findings do not generalize to US-made generics using US-made APIs but could be relevant to US-made branded drugs using imported APIs. Conclusion: Tariffs could raise costs for US drug manufacturers using imported APIs, potentially limiting affordability and manufacturers’ competitiveness in United States and global markets. Policies to incentivize “made-in-America” prescription drugs should incentivize domestic API production or reconsider API tariffs.
- 23 December 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (2)
Open AccessPotential impact of tariffs on active pharmaceutical ingredients on the price of US-made generic drugs
Introduction: The impact of tariffs on prescription drug prices has been poorly understood. Methods: Using US importation data 2019-2024, this study modeled the potential impact of tariffs on the prices of generic drugs manufactured in the United States with imported active pharmaceutical ingredients (APIs). Results: Under baseline assumptions a 100% worldwide tariff would result in average price increase of 30% (additional $21.15 per prescription) and a blended tariff based on rates proposed by the Federal Administration would result in an average price increase of 10% (additional $6.22 per prescription) for domestically produced generics using imported APIs. Estimates varied across drugs reflecting different API importation patterns. Assumptions on the tariff rate, the contribution of the API cost to the final drug price, and on the supply chain's ability to absorb the added tariff contributed markedly to determining the final price. The study findings do not generalize to US-made generics using US-made APIs but could be relevant to US-made branded drugs using imported APIs. Conclusion: Tariffs could raise costs for US drug manufacturers using imported APIs, potentially limiting affordability and manufacturers’ competitiveness in United States and global markets. Policies to incentivize “made-in-America” prescription drugs should incentivize domestic API production or reconsider API tariffs.
- Open Access
Plant and Animal-Based Dietary Patterns and Cardiometabolic Diseases in the Brazilian Population: Cross-Sectional Analysis of the Brazilian National Health Survey
Background: Brazil’s dietary patterns and significant socioeconomic and geographic diversity present unique challenges for the prevention of cardiometabolic diseases. Methods: In this cross-sectional study, we analyzed data from a nationwide representative survey to understand how dietary patterns related to cardiometabolic diseases. We classified the dietary pattern of participants as whole plant-based, processed plant-based, and animal-based. Then, they were categorized into high, intermediate, and low consumption. Logistic regression analysis was used to test the prevalence of obesity, hypertension, hypercholesterolemia, diabetes, stroke, and heart diseases according to the level of intake of each of the three dietary patterns. Results: Compared to the low intake of a whole plant-based dietary pattern, a high intake was associated with a lower prevalence of obesity (OR 0.64; 95% CI 0.54, 0.75) and hypercholesterolemia (OR 0.69, 95% CI 0.56, 0.85). A processed plant-based dietary pattern (including items such as soda and sweets) was inversely associated with the prevalence of obesity (OR 0.90; 95% CI 0.83, 0.97), hypertension (OR 0.82; 95% CI 0.76, 0.88), hypercholesterolemia (OR 0.81; 95% CI 0.74, 0.88), and diabetes (OR 0.53; 95% CI 0.48, 0.59). A high intake of animal-based dietary patterns was associated with a lower prevalence of heart diseases (OR: 0.60; 95% CI 0.40, 0.90). Conclusions: In this cross-sectional analysis, greater adherence to specific dietary patterns was associated with differences in the prevalence of cardiometabolic conditions. However, causality cannot be established, and longitudinal studies are warranted to confirm these findings.
Open AccessPlant and Animal-Based Dietary Patterns and Cardiometabolic Diseases in the Brazilian Population: Cross-Sectional Analysis of the Brazilian National Health Survey
Background: Brazil’s dietary patterns and significant socioeconomic and geographic diversity present unique challenges for the prevention of cardiometabolic diseases. Methods: In this cross-sectional study, we analyzed data from a nationwide representative survey to understand how dietary patterns related to cardiometabolic diseases. We classified the dietary pattern of participants as whole plant-based, processed plant-based, and animal-based. Then, they were categorized into high, intermediate, and low consumption. Logistic regression analysis was used to test the prevalence of obesity, hypertension, hypercholesterolemia, diabetes, stroke, and heart diseases according to the level of intake of each of the three dietary patterns. Results: Compared to the low intake of a whole plant-based dietary pattern, a high intake was associated with a lower prevalence of obesity (OR 0.64; 95% CI 0.54, 0.75) and hypercholesterolemia (OR 0.69, 95% CI 0.56, 0.85). A processed plant-based dietary pattern (including items such as soda and sweets) was inversely associated with the prevalence of obesity (OR 0.90; 95% CI 0.83, 0.97), hypertension (OR 0.82; 95% CI 0.76, 0.88), hypercholesterolemia (OR 0.81; 95% CI 0.74, 0.88), and diabetes (OR 0.53; 95% CI 0.48, 0.59). A high intake of animal-based dietary patterns was associated with a lower prevalence of heart diseases (OR: 0.60; 95% CI 0.40, 0.90). Conclusions: In this cross-sectional analysis, greater adherence to specific dietary patterns was associated with differences in the prevalence of cardiometabolic conditions. However, causality cannot be established, and longitudinal studies are warranted to confirm these findings.
- Open Access
- 22 October 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (11) , 780-790
Developing New Drugs for the COVID ‐19 Emergency: Anatomy of the U.S. Response
Context: To meet the need for effective treatments during the COVID‐19 Public Health Emergency, the U.S. government sought to accelerate the discovery and development of new antiviral treatments—a process that normally took 4–12 years. The government changed many features of the established system, selecting the investigational drugs, sponsoring or conducting the clinical testing, and purchasing and managing the distribution of the successful products. Methods: We focused on novel therapeutic agents for COVID‐19 that were funded, clinically tested, and/or received Emergency Use Authorization during the Public Health Emergency from January 2020 to May 2023. The primary sources were the public records of the National Institutes of Health, the U.S. Food and Drug Administration, and the Biomedical Advanced Research and Development Authority. Excluded were vaccines, devices, diagnostic tests, and new indications for approved drugs. Results: In less than 24 months, the emergency program developed, tested, approved, and distributed eight new therapeutic products, including six monoclonal antibodies and two new oral antivirals. In addition, 11 other investigational agents were funded or tested under the emergency program but did not receive Emergency Use Authorization. More than 30 million courses of treatment were distributed at a cost of $29 billion or $881 per patient. By the end of the emergency, viral mutations and rapidly growing population immunity rendered the new products ineffective in almost all patients. Conclusions: The emergency program was dramatically effective in finding and testing new drug treatments using a variety of clinically relevant endpoints and serving varied patient populations. Planning for future pandemics should include a global network of clinical testing centers that were key to a rapid response. Research is needed to discover more durable antiviral treatments, especially in settings where mutation and population immunity are subject to rapid change.
- 22 October 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (11) , 780-790
Open AccessDeveloping New Drugs for the COVID ‐19 Emergency: Anatomy of the U.S. Response
Context: To meet the need for effective treatments during the COVID‐19 Public Health Emergency, the U.S. government sought to accelerate the discovery and development of new antiviral treatments—a process that normally took 4–12 years. The government changed many features of the established system, selecting the investigational drugs, sponsoring or conducting the clinical testing, and purchasing and managing the distribution of the successful products. Methods: We focused on novel therapeutic agents for COVID‐19 that were funded, clinically tested, and/or received Emergency Use Authorization during the Public Health Emergency from January 2020 to May 2023. The primary sources were the public records of the National Institutes of Health, the U.S. Food and Drug Administration, and the Biomedical Advanced Research and Development Authority. Excluded were vaccines, devices, diagnostic tests, and new indications for approved drugs. Results: In less than 24 months, the emergency program developed, tested, approved, and distributed eight new therapeutic products, including six monoclonal antibodies and two new oral antivirals. In addition, 11 other investigational agents were funded or tested under the emergency program but did not receive Emergency Use Authorization. More than 30 million courses of treatment were distributed at a cost of $29 billion or $881 per patient. By the end of the emergency, viral mutations and rapidly growing population immunity rendered the new products ineffective in almost all patients. Conclusions: The emergency program was dramatically effective in finding and testing new drug treatments using a variety of clinically relevant endpoints and serving varied patient populations. Planning for future pandemics should include a global network of clinical testing centers that were key to a rapid response. Research is needed to discover more durable antiviral treatments, especially in settings where mutation and population immunity are subject to rapid change.
- Open Access
- 3 October 2025
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 6 (10) , e253871
US Antibiotic Importation and Supply Chain Vulnerabilities
Importance: The US has faced persistent antibiotic shortages over the past decade, compromising patient care, public health, and national security. Understanding the global sources of US antibiotic imports is critical to inform policies to improve supply chain resilience.Objective: To identify the global sources of US antibiotic imports, focusing on finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs) between 1992 and 2024.Design and Setting: This cross-sectional study of US antibiotic importation records used data from USA Trade Online from January 1992 to July 2024. Data included import volumes, costs, and the originating country.Main Outcomes and Measures: Trends in annual import volumes for antibiotic FDFs and APIs (metric tons), spending and price per kilogram (inflation-adjusted dollars), and market concentration measured by the Herfindahl-Hirschman Index (HHI). An HHI less than 1500 indicates an unconcentrated (ie, competitive) market, 1500 to 2500 indicates a moderate concentration, and greater than 2500 indicates high concentration.Results: The final sample included 50 FDF-originating countries and 52 API-originating countries. Compared with the annual volume of US antibiotic FDF imports in 1992, the annual volume in 2024 increased 2595.0%, while the annual volume of API imports remained relatively stable. Mean inflation-adjusted importation prices for FDFs decreased from $1836.03 per kg in 1992 to $177.44 per kg in 2024. For APIs, mean prices decreased from $351.74 per kg in 2003 to $65.69 per kilogram in 2024. From 2020 to 2024, India was the leading originating country for FDFs (31.9% of the total imported volume and 18.2% of the total imported cost), followed by Italy (13.4% of the total volume and 22.4% of the total cost). China was the leading originating country for APIs (62.6% of the total imported volume and 28.7% of the total cost), followed by Bulgaria (16.1% of the total volume and 3.8% of the total cost). Italy was the originating country for 2.6% of API imported volume but accounted for 27.9% of the importation costs. HHI revealed that FDF importation has become unconcentrated since 2020 (HHI, 1500-2500), while API importation markets are highly concentrated (2024 HHI, >5000).Conclusions and Relevance: This study found that US antibiotic importation relies on diversified global sources for FDFs but primarily on China for APIs. Policies to strengthen domestic production and diversify sourcing are critical to mitigate supply chain vulnerabilities. Improved traceability and targeted strategies for specific antibiotics are recommended to safeguard public health and national security.
- 3 October 2025
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 6 (10) , e253871
Open AccessUS Antibiotic Importation and Supply Chain Vulnerabilities
Importance: The US has faced persistent antibiotic shortages over the past decade, compromising patient care, public health, and national security. Understanding the global sources of US antibiotic imports is critical to inform policies to improve supply chain resilience.Objective: To identify the global sources of US antibiotic imports, focusing on finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs) between 1992 and 2024.Design and Setting: This cross-sectional study of US antibiotic importation records used data from USA Trade Online from January 1992 to July 2024. Data included import volumes, costs, and the originating country.Main Outcomes and Measures: Trends in annual import volumes for antibiotic FDFs and APIs (metric tons), spending and price per kilogram (inflation-adjusted dollars), and market concentration measured by the Herfindahl-Hirschman Index (HHI). An HHI less than 1500 indicates an unconcentrated (ie, competitive) market, 1500 to 2500 indicates a moderate concentration, and greater than 2500 indicates high concentration.Results: The final sample included 50 FDF-originating countries and 52 API-originating countries. Compared with the annual volume of US antibiotic FDF imports in 1992, the annual volume in 2024 increased 2595.0%, while the annual volume of API imports remained relatively stable. Mean inflation-adjusted importation prices for FDFs decreased from $1836.03 per kg in 1992 to $177.44 per kg in 2024. For APIs, mean prices decreased from $351.74 per kg in 2003 to $65.69 per kilogram in 2024. From 2020 to 2024, India was the leading originating country for FDFs (31.9% of the total imported volume and 18.2% of the total imported cost), followed by Italy (13.4% of the total volume and 22.4% of the total cost). China was the leading originating country for APIs (62.6% of the total imported volume and 28.7% of the total cost), followed by Bulgaria (16.1% of the total volume and 3.8% of the total cost). Italy was the originating country for 2.6% of API imported volume but accounted for 27.9% of the importation costs. HHI revealed that FDF importation has become unconcentrated since 2020 (HHI, 1500-2500), while API importation markets are highly concentrated (2024 HHI, >5000).Conclusions and Relevance: This study found that US antibiotic importation relies on diversified global sources for FDFs but primarily on China for APIs. Policies to strengthen domestic production and diversify sourcing are critical to mitigate supply chain vulnerabilities. Improved traceability and targeted strategies for specific antibiotics are recommended to safeguard public health and national security.
- Open Access
- 28 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Trends in Venture Capital Investment in AI-Driven Biopharmaceutical Startups (Preprint)
UNSTRUCTURED This study analyzes 2010-2024 venture capital trends in international artificial intelligence–driven biopharmaceutical startups, revealing rapid growth in discovery tool investments and concentrated US funding in California and Massachusetts.
- 28 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessTrends in Venture Capital Investment in AI-Driven Biopharmaceutical Startups (Preprint)
UNSTRUCTURED This study analyzes 2010-2024 venture capital trends in international artificial intelligence–driven biopharmaceutical startups, revealing rapid growth in discovery tool investments and concentrated US funding in California and Massachusetts.